Prevalence of remission in selected published reports of rheumatoid arthritis (RA) clinical trials following a tight control strategy and RA clinical cohorts, 1999–2013+.
| Author, Year, (Reference) | Patients | Prevalence of Remission; Criteria |
|---|---|---|
| Treatment strategy clinical trials | ||
| Möttönen, 199920 | Finnish RA Combination Therapy (FIN-RACo) trial | 25% combination therapy; ACR 1981; 11% single-drug therapy; ACR 1981 |
| Grigor, 200421 | Tight Control for Rheumatoid Arthritis (TICORA) trial; single-blind RCT | 65% intensive group; DAS; 16% usual care group; DAS |
| Verstappen, 200722 | Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA) study; open-label strategy trial | 50% intensive group; Utrecht criteria*; 37% conventional group Utrecht criteria* |
| Klarenbeek, 201123 | BehandelStrategien (BeSt) or “treatment strategies” trial | 23% drug-free remission |
| Hetland, 201224 | Ciclosporine, Methotrexate, Steroid in RA (CIMESTRA) | 56%; Boolean; 78%; DAS28 |
| Wevers-de Boer, 201225 | Induction therapy with MTX and Prednisone in Rheumatoid Or Very Early arthritic Disease (IMPROVED) trial; 2-step treatment strategy study in Dutch early arthritis patients | 60%; Boolean |
| Clinical cohorts | ||
| van der Woude, 200926 | Leiden Early Arthritis Clinic (EAC) and British Early Rheumatoid Arthritis Study (ERAS) | 21.4% Leiden EAC; modified ACR 15%; Leiden EAC; DMARD-free; 9.4% ERAS; DMARD-free |
| Shahouri, 201127 | US Department of Veterans Affairs RA (VARA) registry Arthritis and Rheumatology Clinics of Kansas (ARCK) | 24.0% VARA; DAS28; 7.0% VARA; Boolean; 28.3% ARCK; DAS28; 6.9% ARCK; CDAI |
| de Punder, 201228 | Dutch Rheumatoid Arthritis Monitoring (DREAM) biologic registry | 6%; DAS28 |
| Prince, 201229 | Brigham and Women’s Rheumatoid Arthritis Sequential Study (BRASS) | 31%; DAS28 < 2.6; 10%; Boolean |
| Castrejón, 201317 | Etude et Suivi des Polyarthrites Indifférenciées Récentes (ESPOIR) French early arthritis cohort | 32.5%; DAS28; 12.9%; Boolean |
| Navarro-Millan, 201330 | Consortium of Rheumatology Researchers of North America (CORRONA), 2001–2011 | 8%; Boolean |
| Thiele, 201331 | German Collaborative Centers, 2007–2009 | 28%; DAS28; 7%; Boolean |
↵+ Where a study reported remission according to multiple criteria, the criteria with the highest and lowest percentages of patients in remission are presented.
↵* Utrecht criteria for remission = no swollen joint, and at least 2 of the following: TJC ≤ 3, erythrocyte sedimentation rate ≤ 20 mm/h and visual analog scale general well being ≤ 20 mm22. DAS28: Disease Activity Score 28 joint; MTX: methotrexate; ACR: American College of Rheumatology; DMARD: disease-modifying antirheumatic drugs; CDAI: Clinical Disease Activity Index.